Literature DB >> 20713120

Targeting human Rad51 by specific DNA aptamers induces inhibition of homologous recombination.

Susan F Martinez1, Axelle Renodon-Cornière, Julian Nomme, Damien Eveillard, Fabrice Fleury, Masayuki Takahashi, Pierre Weigel.   

Abstract

Human Rad51 (HsRad51), a key element of the homologous recombination repair pathway, is related to the resistance of cancer cells to chemo- and radio-therapies. This protein is thus a good target for the development of anti-cancer treatments. We have searched for new inhibitors directed against HsRad51 using the Systematic Evolution of Ligands by EXponential enrichment (SELEX) approach. We have selected three aptamers displaying strong effects on strand exchange activity. Analysis by circular dichroism shows that they are highly structured DNA molecules. Our results also show that they affect the first step of the strand exchange reaction by promoting the dissociation of DNA from the ATP/HsRad51/DNA complex. Moreover, these inhibitors bind only weakly to RecA, a prokaryotic ortholog of HsRad51. Both the specificity and the efficiency of their inhibition of recombinase activity offer an analytical tool based on molecular recognition and the prospect of developing new therapeutic agents.
Copyright © 2010 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20713120     DOI: 10.1016/j.biochi.2010.08.006

Source DB:  PubMed          Journal:  Biochimie        ISSN: 0300-9084            Impact factor:   4.079


  7 in total

Review 1.  Synthetic Lethality through the Lens of Medicinal Chemistry.

Authors:  Samuel H Myers; Jose Antonio Ortega; Andrea Cavalli
Journal:  J Med Chem       Date:  2020-11-02       Impact factor: 7.446

2.  Targeting RAD51 phosphotyrosine-315 to prevent unfaithful recombination repair in BCR-ABL1 leukemia.

Authors:  Artur Slupianek; Yashodhara Dasgupta; Shu-Yue Ren; Ewa Gurdek; Milene Donlin; Margaret Nieborowska-Skorska; Fabrice Fleury; Tomasz Skorski
Journal:  Blood       Date:  2011-06-07       Impact factor: 22.113

3.  Dual and Opposite Effects of hRAD51 Chemical Modulation on HIV-1 Integration.

Authors:  Sylvain Thierry; Mohamed Salah Benleulmi; Ludivine Sinzelle; Eloise Thierry; Christina Calmels; Stephane Chaignepain; Pierre Waffo-Teguo; Jean-Michel Merillon; Brian Budke; Jean-Max Pasquet; Simon Litvak; Angela Ciuffi; Patrick Sung; Philip Connell; Ilona Hauber; Joachim Hauber; Marie-Line Andreola; Olivier Delelis; Vincent Parissi
Journal:  Chem Biol       Date:  2015-06-04

4.  The homologous recombination protein RAD51 is a promising therapeutic target for cervical carcinoma.

Authors:  Qian Chen; Dongge Cai; Mu Li; Xiaoling Wu
Journal:  Oncol Rep       Date:  2017-06-15       Impact factor: 3.906

5.  Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51.

Authors:  Jung Ok Lee; Min Ju Kang; Won Seok Byun; Shin Ae Kim; Il Hyeok Seo; Jeong Ah Han; Ji Wook Moon; Ji Hae Kim; Su Jin Kim; Eun Jung Lee; Serk In Park; Sun Hwa Park; Hyeon Soo Kim
Journal:  Breast Cancer Res       Date:  2019-10-22       Impact factor: 6.466

6.  RI-1: a chemical inhibitor of RAD51 that disrupts homologous recombination in human cells.

Authors:  Brian Budke; Hillary L Logan; Jay H Kalin; Anna S Zelivianskaia; William Cameron McGuire; Luke L Miller; Jeremy M Stark; Alan P Kozikowski; Douglas K Bishop; Philip P Connell
Journal:  Nucleic Acids Res       Date:  2012-05-09       Impact factor: 16.971

7.  Contributions of the RAD51 N-terminal domain to BRCA2-RAD51 interaction.

Authors:  Shyamal Subramanyam; William T Jones; Maria Spies; M Ashley Spies
Journal:  Nucleic Acids Res       Date:  2013-08-08       Impact factor: 16.971

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.